Results 61 to 70 of about 274,716 (345)

The role of the brain renin-angiotensin system in Parkinson´s disease

Translational Neurodegeneration
The renin-angiotensin system (RAS) was classically considered a circulating hormonal system that regulates blood pressure. However, different tissues and organs, including the brain, have a local paracrine RAS.
Jose Luis Labandeira-Garcia, Carmen M. Labandeira, Maria J. Guerra, Ana I. Rodriguez-Perez   +3 more
doaj   +1 more source

Primary skin fibroblasts as a model of Parkinson's disease [PDF]

, 2012
Parkinson's disease is the second most frequent neurodegenerative disorder. While most cases occur sporadic mutations in a growing number of genes including Parkin (PARK2) and PINK1 (PARK6) have been associated with the disease.
A Grunewald, A Grunewald, A Petit, A Rakovic, A Sajadi, A Sprenger, AL Fridman, AL Fridman, AW Michell, B Stefano Di, Blas Morales-Gordo, C Mytilineou, C Piccoli, CA Costa da, CM Clements, DP Narendra, DT Woodley, E Fernandez-Espejo, EM Valente, F Pan-Montojo, F Soldner, FR Wiedemann, G Tesco, Georg Auburger, GP Connolly, H Braak, H Jiang, H Mortiboys, Heinz Reichmann, HH Hoepken, HH Hoepken, HM Huang, HM Huang, IF Khan, IH Park, J Hoenicka, J Waak, Jessica Drost, JM Harper, K Bayreuther, K Gorner, K Isobe, K Winkler-Stuck, Katrin Marcus, KH Narsinh, L Gasparini, L Grandoso, LS Tain, M Garcia-Arencibia, M Ikemura, M Jendrach, M Klinkenberg, M Sun, M Varma, M Wernig, Marina Jendrach, MB Graeber, MC Maj, Michael Klinkenberg, N Exner, N Hirashima, O Rothfuss, P Hoyo del, P Rieske, R Djaldetti, R Musanti, S Geisler, S Gispert, S Kaneko, S Mai, SM Hussein, Suzana Gispert, T Amo, T Gasser, T Shishido, Ulrich Brandt, Vania Broccoli, WG Tatton, Wolfram S. Kunz, WY Lee, Y Miki, Y Ren, Y Ren, YC Kim, Z Jingzhong   +84 more
core   +1 more source

Longitudinal Study of Salivary Biomarkers in the Definition of Clinico‐Molecular Progression of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
Longitudinal changes in salivary biomarkers in Parkinson’s disease (PD) from early (T0) to 4‐year follow‐up (T1), quantified by ELISA: oligomeric and total α‐synuclein, total and phosphorylated tau, MAP1LC3B (autophagy), and TNFa (inflammation). Blue arrows indicate direction of change at T1 vs T0 (up = increase; down = decrease).
Maria Ilenia De Bartolo, Daniele Belvisi, Matteo Costanzo, Claudia Caturano, Francesco Emanuele Bellomi, Carolina Cutrona, Flavia Aiello, Giorgio Leodori, Massimo Marano, Romina Mancinelli, Antonella Conte, Giovanni Fabbrini, Alfredo Berardelli, Giorgio Vivacqua   +13 more
wiley   +1 more source

Inhibition of Protease-Activated Receptor-2 Activation in Parkinson’s Disease Using 1-Piperidin Propionic Acid

Biomedicines
In Parkinson’s disease, neuroinflammation is a double-edged sword; when inflammation occurs it can have harmful effects, despite its important role in battling infections and healing tissue.
Santina Quarta, Michele Sandre, Mariagrazia Ruvoletto, Marta Campagnolo, Aron Emmi, Alessandra Biasiolo, Patrizia Pontisso, Angelo Antonini   +7 more
doaj   +1 more source

Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.

PLoS Biology, 2018
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson disease. Genetics and neuropathology link Parkinson disease with the microtubule-binding protein tau, but the mechanism of action of LRRK2 mutations and the
Farah H Bardai, Dalila G Ordonez, Rachel M Bailey, Matthew Hamm, Jada Lewis, Mel B Feany   +5 more
doaj   +1 more source

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

Translational Neurodegeneration, 2019
Background IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without ...
Franziska Hopfner, Stefanie H. Müller, Dagmar Steppat, Joanna Miller, Nele Schmidt, Klaus-Peter Wandinger, Frank Leypoldt, Daniela Berg, Andre Franke, Wolfgang Lieb, Lukas Tittmann, Monika Balzer-Geldsetzer, Simon Baudrexel, Richard Dodel, Ruediger Hilker-Roggendorf, Elke Kalbe, Jan Kassubek, Thomas Klockgether, Inga Liepelt-Scarfone, Brit Mollenhauer, Petra Neuser, Kathrin Reetz, Oliver Riedel, Claudia Schulte, Jörg B. Schulz, Annika Spottke, Alexander Storch, Claudia Trenkwalder, Hans-Ulrich Wittchen, Karsten Witt, Ullrich Wüllner, Günther Deuschl, Gregor Kuhlenbäumer   +32 more
doaj   +1 more source

Effects of adaptive-tempo music-based RAS for Parkinson’s disease patients [PDF]

, 2017
The use of Rhythmic Auditory Stimulation (RAS) is a potential method to help Parkinson Patients improve their gait characteristics. By providing auditory stimuli such as a metronome or music, gait impairments, which characterize the illness, tend to ...
Blomme, Jana, Cambier, Dirk, De Wilde, Wim, Dotov, Dobri, Leman, Marc, Lesaffre, Micheline, Moens, Bart, Santens, Patrick, Soens, Heleen, Van Noorden, Leon   +9 more
core   +2 more sources

Emergence of nonmotor symptoms as the focus of research and treatment of Parkinson's disease: Introduction to the special section on nonmotor dysfunctions in Parkinson's disease [PDF]

, 2013
Parkinson's disease (PD) is traditionally characterized by the cardinal motor symptoms of tremor, rigidity, slowness of movement, and impairments of posture, gait, and balance.
Cronin-Golomb, Alice
core   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

Feasibility of a Pharmabuddy Care Service for patients with Parkinson’s disease

BMC Health Services Research
Background Pharmaceutical care for patients with Parkinson’s disease (PD) is complex. Specialized pharmaceutical care provided by a dedicated pharmacy team member (pharmabuddy) for these patients may reduce medication-related problems. The feasibility of
C. C. M. Stuijt, F. Karapinar-Çarkit, C. van de Steeg – van Gompel, T. van Laar, B. J. F. van den Bemt, M. Heringa   +5 more
doaj   +1 more source